Patients with osteoarthritis in the knee and hip, but not the hand, have an increased risk for venous thromboembolism, which may be exacerbated by knee and hip replacements, researchers report.

Patients with osteoarthritis in the knee and hip, but not the hand, have an increased risk for venous thromboembolism, which may be exacerbated by knee and hip replacements, researchers report.

Real-world study findings suggest that people with rheumatoid arthritis treated with the JAK inhibitor baricitinib may have a higher risk for venous thromboembolism than those on TNF inhibitors.

These groups include people aged 65 years and older and those with risk factors for cardiovascular disease, cancer, and venous thromboembolism.

Results from a retrospective analysis suggest that cytomegalovirus seropositivity at ANCA-associated vasculitis diagnosis is an independent risk factor for developing venous thromboembolism.

“Generally those are not risk factors which are really applicable to our patient population, nor is thromboembolism,” said Ramanan, but he pointed out that there was one case of pulmonary embolism during baricitinib treatment in JUVE-BASIS.

medwireNews : Research shows that the risk for venous thromboembolism (VTE) is significantly related to the presence of autoantibodies associated with rheumatoid arthritis (RA).

Recurrent venous thromboembolism is more common in people with granulomatosis with polyangiitis than among individuals in the general population who had an unprovoked first event, US researchers report in Rheumatology Advances in Practice.

They make reference to recent concerns over herpes zoster infections with JAK inhibitors, which occurred at the highest dose in eight of the studies, and the risk for venous thromboembolism, for which many of the studies had insufficient data.

Analysis of data from the NORD-STAR study suggests that people with early rheumatoid arthritis have increased levels of coagulation biomarkers, putting them at increased risk for venous thromboembolism, and initial treatment with DMARDs can help reduce this imbalance.

Together with colleagues, she assessed the rate of MACE and venous thromboembolism (VTE) with JAK inhibitors versus TNF inhibitors using the World Health Organization Global Individual Case Safety Report database (VigiBase®).

Serious infections were increased in baricitinib-treated patients, noted Morand, but “importantly there was no increase in venous thromboembolism events in baricitinib-treated groups.”

People with psoriatic arthritis have an increased risk for venous thromboembolism relative to the general population, and this association is likely to be related to underlying comorbidities, research suggests.

Click through for more information on this announcement

There were no cases of major cardiovascular events, venous thromboembolism, severe vascular symptoms, or gastrointestinal perforation.

Infection and VTE risk   The final two presentations on ORAL Surveillance reported on two of the secondary outcomes of the trial, namely infection and venous thromboembolism (VTE) risk.

A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.

These oral agents offer a number of potential advantages for people with inflammatory arthritis, but some safety concerns have emerged, including a possible increased risk for venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy.

A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.